Verastem (VSTM) News Today $5.52 +0.13 (+2.41%) Closing price 01/22/2025 04:00 PM EasternExtended Trading$5.52 0.00 (0.00%) As of 08:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Verastem Expands Oncology Pipeline with VS-7375 AcquisitionJanuary 23 at 8:09 AM | tipranks.comVerastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven CancersJanuary 23 at 8:02 AM | businesswire.comBarclays PLC Has $167,000 Stake in Verastem, Inc. (NASDAQ:VSTM)Barclays PLC raised its stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) by 546.7% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 55,708 shares of the biopharmaceutical company's stock after purchasing an additional 47,094 shares during the pJanuary 23 at 3:05 AM | marketbeat.comVerastem appoints new COO with extensive biotech experienceJanuary 22 at 4:54 AM | msn.comVerastem Appoints Matthew E. Ros as COOJanuary 21 at 5:13 PM | tipranks.comVerastem Secures $150 Million Note Purchase Agreement with Oberland CapitalJanuary 20 at 2:06 AM | americanbankingnews.comVerastem appoints Matthew Ros as COOJanuary 16, 2025 | markets.businessinsider.comVerastem Oncology Appoints Matthew Ros As COO, Stock Up In Pre-MarketJanuary 15, 2025 | markets.businessinsider.comVerastem Oncology Names Matthew E. Ros as Chief Operating OfficerJanuary 15, 2025 | businesswire.comVerastem exercises early option to license VS-7375 from GenFleet TherapeuticsJanuary 14, 2025 | markets.businessinsider.comDan Paterson Sells 8,568 Shares of Verastem, Inc. (NASDAQ:VSTM) StockVerastem, Inc. (NASDAQ:VSTM - Get Free Report) CEO Dan Paterson sold 8,568 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $5.24, for a total transaction of $44,896.32. Following the completion of the sale, the chief executive officer now owns 347,581 shares of the company's stock, valued at approximately $1,821,324.44. This trade represents a 2.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.January 14, 2025 | marketbeat.comVerastem Exercises Early Option To License From GenFleet VS-7375 - Quick FactsJanuary 14, 2025 | markets.businessinsider.comVerastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025January 13, 2025 | businesswire.comGeode Capital Management LLC Raises Stock Position in Verastem, Inc. (NASDAQ:VSTM)Geode Capital Management LLC lifted its stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 67.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 890,599 shares of the biopharmaceutical company's stock after buyiJanuary 8, 2025 | marketbeat.comVerastem (VSTM) Gets a Buy from RBC CapitalJanuary 7, 2025 | markets.businessinsider.comVerastem price target raised to $16 from $13 at RBC CapitalJanuary 7, 2025 | markets.businessinsider.comRoyal Bank of Canada Issues Positive Forecast for Verastem (NASDAQ:VSTM) Stock PriceRoyal Bank of Canada boosted their price target on Verastem from $13.00 to $16.00 and gave the stock an "outperform" rating in a research report on Tuesday.January 7, 2025 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Buy" from AnalystsShares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have been given an average rating of "Buy" by the nine brokerages that are currently covering the company, Marketbeat.com reports. Nine research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerJanuary 4, 2025 | marketbeat.comVerastem: Planning The PDUFA Run-UpJanuary 3, 2025 | seekingalpha.comVerastem: BLA Acceptance Puts Key Goals In SightJanuary 2, 2025 | seekingalpha.comVerastem: BLA Acceptance Puts Key Goals In SightJanuary 2, 2025 | seekingalpha.comVerastem Shares Soar on FDA Priority Review of Cancer TreatmentJanuary 1, 2025 | marketwatch.comBiggest stock movers Tuesday: VSTM, DAVE, SGMO and moreJanuary 1, 2025 | msn.comWhy Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?December 31, 2024 | benzinga.comFDA sets priority review date for Verastem’s new ovarian cancer drugDecember 31, 2024 | bizjournals.comVerastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy ApplicationDecember 31, 2024 | gurufocus.comVerastem (NASDAQ:VSTM) Price Target Raised to $20.00 at BTIG ResearchBTIG Research upped their price target on Verastem from $13.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday.December 31, 2024 | marketbeat.comBiggest stock movers Tuesday: VSTM, ACADDecember 31, 2024 | msn.comVerastem price target raised to $20 from $13 at BTIGDecember 31, 2024 | markets.businessinsider.comFDA To Decide On Verastem's Avutometinib & Defactinib For A Subtype Of Serous Ovarian Cancer In JuneDecember 31, 2024 | markets.businessinsider.comVerastem announces FDA acceptance and Priority Review of NDA for AvutometinibDecember 30, 2024 | markets.businessinsider.comFDA accepts Verastem NDA for ovarian cancer drug comboDecember 30, 2024 | msn.comVerastem jumps 50% to $5.50 on FDA priority review for AvutometinibDecember 30, 2024 | markets.businessinsider.comFDA accepts Verastem NDA for priority review, stock jumps 20% (update)December 30, 2024 | seekingalpha.comVerastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS ...December 30, 2024 | businesswire.comVerastem Oncology's New Cancer Treatment Gets FDA Priority ReviewDecember 30, 2024 | marketwatch.comVerastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian CancerDecember 30, 2024 | businesswire.comVerastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous OvariDecember 30, 2024 | investing.comVerastem, Inc. (NASDAQ:VSTM) Short Interest Up 31.0% in DecemberVerastem, Inc. (NASDAQ:VSTM - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 2,620,000 shares, an increase of 31.0% from the November 30th total of 2,000,000 shares. Approximately 6.6% of the company's stock are sold short. Based on an average daily volume of 983,100 shares, the days-to-cover ratio is presently 2.7 days.December 28, 2024 | marketbeat.comVerastem director Robert Gagnon sells $1,862 in stockDecember 20, 2024 | investing.comVerastem director Brian Stuglik sells $4,160 in stockDecember 20, 2024 | investing.comVerastem price target raised to $9 from $7 at MizuhoDecember 20, 2024 | markets.businessinsider.comVerastem (NASDAQ:VSTM) Given New $9.00 Price Target at MizuhoMizuho increased their price target on Verastem from $7.00 to $9.00 and gave the company an "outperform" rating in a research report on Thursday.December 19, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Verastem (NASDAQ:VSTM)HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Verastem in a report on Thursday.December 19, 2024 | marketbeat.comVerastem announces preliminary avutometinib and sotorasib dataDecember 18, 2024 | markets.businessinsider.comMizuho Securities Keeps Their Buy Rating on Verastem (VSTM)December 18, 2024 | markets.businessinsider.comVerastem Oncology's Triplet Combination Shows No Dose-Limiting Toxicities In RAMP 203 TrialDecember 18, 2024 | markets.businessinsider.comVerastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung CancerDecember 18, 2024 | businesswire.comVerastem (NASDAQ:VSTM) Stock Crosses Above 200 Day Moving Average - Here's WhyVerastem (NASDAQ:VSTM) Share Price Passes Above 200-Day Moving Average - What's Next?December 18, 2024 | marketbeat.comVerastem’s Promising Drug Combination for LGSOC: Analyst Recommends Buy RatingDecember 17, 2024 | markets.businessinsider.com Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address VSTM Media Mentions By Week VSTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VSTM News Sentiment▼0.580.64▲Average Medical News Sentiment VSTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VSTM Articles This Week▼53▲VSTM Articles Average Week Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ironwood Pharmaceuticals News Emergent BioSolutions News Codexis News Rigel Pharmaceuticals News XOMA News Vanda Pharmaceuticals News Sangamo Therapeutics News Lexicon Pharmaceuticals News Achieve Life Sciences News Agenus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VSTM) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
